Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
ED Recovery in Men Age </=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy for Prostate Cancer
NCT00544076 · City of Hope Medical Center · PHASE3 · terminated · last registry update 2019-01-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Accrual too slow” | – | Registry record, City of Hope Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE5A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-11-06Phase 3 first posted: Erasmus Medical Center, Pentoxifylline (NCT04152980)
- 2019-08-15Phase 3 first posted: MediciNova, MN-166 + placebo (NCT04057898)
- 2019-07-31Phase 3 first posted: National Jewish Health, Sildenafil 40mg oral capsule + Placebo Oral capsule (NCT04039087)
- 2019-07-31Phase 3 first posted: Johns Hopkins University, Mono-Therapy with Sildenafil + Duo-Therapy with Sildenafil + Bosentan (NCT04039464)
- 2019-06-25Phase 3 first posted: University Hospital, Montpellier, Sildenafil + Placebos (NCT03997097)
- 2019-04-05Phase 3 first posted: Actelion, FDC macitentan/tadalafil + Macitentan 10 mg (NCT03904693)
- 2018-09-26Phase 3 first posted: Rennes University Hospital, Sildenafil + Placebo (NCT03686306)
- 2018-02-13Phase 3 first posted: Mezzion Pharma Co. Ltd, Udenafil (NCT03430583)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision